Two Appointed to ONI’s Editorial Advisory Board for Oncology Nursing

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 1
Volume 12
Issue 1

MELVILLE, New York-ONI is pleased to announce the creation of an Editorial Advisory Board for Oncology Nursing, to work with Sharon Krumm, PhD, RN, the Editor of Oncology Nursing, and staff to report research by oncology nurses and issues of special interest to oncology nurses. The first two appointees to the board are Catherine (Cathy) Coleman, RN, OCN, and Mary McCabe, BSN, MA.

MELVILLE, New York—ONI is pleased to announce the creation of an Editorial Advisory Board for Oncology Nursing, to work with Sharon Krumm, PhD, RN, the Editor of Oncology Nursing, and staff to report research by oncology nurses and issues of special interest to oncology nurses. The first two appointees to the board are Catherine (Cathy) Coleman, RN, OCN, and Mary McCabe, BSN, MA.

Ms. Coleman is an oncology certified nurse who has dedicated most of her 30-year nursing career to specializing in diseases of the breast and breast center development. She has been a longstanding volunteer for the American Cancer Society and the State of California Department of Health Services, Cancer Detection Section, and has won many awards for outstanding leadership, education, and volunteer services.

Her interests, publications, and passion focus on the complex challenges associated with creating interdisciplinary, research-driven, and patient-focused comprehensive breast centers. As an independent consultant, Ms. Coleman works with community hospitals, academic medical centers, medical device companies, managed care companies, and community-based organizations committed to better breast care.

In 1986, Ms. Coleman was a founding member of the Board of Trustees of the National Consortium of Breast Centers and currently serves on its board.

For the last 6 years, Ms. McCabe has held a number of positions at the National Cancer Institute that have focused on the development of programs and initiatives specific to clinical trials, cancer education, cancer information, and bioethics. From 1996 to 1999, she was assistant director, Division of Cancer Treatment and Diagnosis, and director, Office of Clinical Research Promotion, where she developed a number of initiatives that are components of the NCI’s implementation plan for restructuring its clinical trials program.

Since 1999, Ms. McCabe has served as the director of Education and Special Initiatives; in this role, she has been responsible for reorganizing and expanding the Institute’s education programs. She also works directly with NCI director Andrew von Eschenbach, MD, on institute-wide clinical trials issues and works with the NIH Department of Clinical Bioethics. For more than a year, Ms. McCabe served as acting director of the NCI’s Office of Communications.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content